Evaluation of Synbiotics in the Prevention of Ventilator‑Associated Pneumonia: A Randomized, Triple‑Blind, Placebo‑Controlled Clinical Trial

Faranak Kasiri, Rasool Soltani, Farzin Khorvash, Behrooz Ataei, Maryam Nasirian, Atousa Hakamifard

Abstract


Background: Ventilator‑associated pneumonia (VAP) is one of the most common nosocomial infections. The role of probiotics in preventing VAP is still questionable. This study aimed at evaluating the effect of synbiotic FamiLact 2plus on the prevention of VAP in patients admitted to the intensive care unit (ICU). Methods: A total of 80 mechanically ventilated patients were included and divided into two groups of 40. Group 1 received FamiLact 2plus, and group 2 received placebo. The outcome variables were compared, including the incidence of VAP, the time interval between the onset of ventilation and VAP, the duration of mechanical ventilation, and the length of stay in the ICU. Results: VAP is documented in four patients (10%) in group 1 and 11 patients (27.5%) in group 2 (P = 0.045). The length of stay in the ICU in group 1 was significantly shorter than in group 2, and the time interval between the start of intubation and the onset of VAP in group 1 was longer than in the placebo group. During the intervention, 15 patients in group 1 (37.5%) and 26 patients in group 2 (65%) developed diarrhea, which was a significant difference (P = 0.02). Conclusions: Synbiotic is associated with a reduction in the incidence of VAP as well as a reduction in ICU stay and delayed VAP.

International Journal of Preventive Medicine 14():124, November 2023. | DOI: 10.4103/ijpvm.ijpvm_329_22

 

Corresponding Author: Dr. Atousa Hakamifard

E‑mail: atousahakamifard@sbmu.ac.ir

You can also search for this author in: PubMed  Google Scholar


Keywords


Incidence; mortality; pneumonia; probiotics; synbiotics; ventilator‑associated pneumonia

Full Text:

PDF

References


Ekren PK, Ranzani OT, Ceccato A, Li BG, Munoz CE, Ferrer M,

et al. Evaluation of the 2016 Infectious Diseases Society of

America/American Thoracic Society guideline criteria for risk of

multidrug‑resistant pathogens in patients with hospital‑acquired

and ventilator‑associated pneumonia in the ICU. Am J Respir

Crit Care Med 2018;197:826‑30.

Bouadma L, Sonneville R, Garrouste‑Org M, Darmon M,

Souweine B, Voiriot G, et al. Ventilatorassociated events:

Prevalence, outcome, and relationship with ventilator‑associated

pneumonia. Crit Care Med 2015;43:1798‑806.

Kalil AC, Metersky ML, Klompas M, Muscedere J, Sweeney DA,

Palmer LB, et al. Management of adults with hospital‑acquired

and ventilator associated pneumonia: 2016 Clinical Practice

Guidelines by the Infectious Diseases Society of America and

the American Thoracic Society. Clin Infect Dis 2016;63:e61‑111.

Kalanuria AA, Ziai W, Mirski M. Ventilator associated

pneumonia in the ICU. Crit Care 2014;18:208.

Lawal O, Muhamadali H, Ahmed WM, White IR, Nijsen TME,

Goodacre R, et al. Headspace volatile organic compounds from

bacteria implicated in ventilator‑associated pneumonia analysed

by TDGC/MS. J Breath Res 2018;12:026002.

Valachis A, Samonis G, Kofteridis DP. The role of aerosolized

colistin in the treatment of ventilatorassociated pneumonia:

A systematic review and metaanalysis. Crit Care Med

;43:527‑33.

Mariyaselvam MZ, Marsh LL, Bamford S, Smith A, Wise MP,

Williams DW. Endotracheal tubes and fluid aspiration: An

in vitro evaluation of new cuff technologies. BMC Anesthesiol

;17:36.

de Carvalho Baptista IM, Martinho FC, Nascimento GG, da

Rocha Santos CE, Prado RFD, Valera MC. Colonization of

oropharynx and lower respiratory tract in critical patients:

Risk of ventilator‑associated pneumonia. Arch Oral Biol

;85:64‑9.

Metersky ML, Wang Y, Klompas M, Eckenrode S, Bakullari A,

Eldridge N. Trend in ventilator associated pneumonia rates

between 2005 and 2013. JAMA 2016;316:2427‑9.

Fawzy M, Genena D, Sewify K. Should probiotics be routinely

used in critically Ill patients? BAOJ Nutrition 2017;3:043.

Kapur R, Kim M, Rebetz J, Takabe‑French A, Kim N,

Shanmugabhavananthan S, et al. Gastrointestinal flora dictates

the biological response in murine transfusion related acute lung

injury (TRALI). Blood 2017;130:766.

Schrezenmeir J, de Vrese M. Probiotics, prebiotics, and

synbiotics‑‑approaching a definition. Am J Clin Nutr

;73(2 Suppl):361S‑4S.

Yahyavi Z, Fazeli MR, Mirfeizi M, Aliebrahimi S, Ostad SN.

Cytotoxic activity of familact: A probiotic supplement. Iran J

Toxicol 2018;12:41‑5.

Razmpoosh E, Javadi M. The Effect of Familact Probiotic

Supplementation on Lipid Profile, Glycemic Control and Insulin

Levels in Patients with Type 2 Diabetes. Doctoral dissertation.

Qazvin university of Medical Sciences; 2015.

Chapat L, Chemin K, Dubois B, Bourdet‑Sicard R, Kaiserlian D.

Lactobacillus casei reduces CD8+ T cellmediated skin

inflammation. Eur J Immunol 2004;34:2520‑8.

Isolauri E, Sutas Y, Kanaanpaa P, Arvilommi J, Salminen S.

Probiotics: Effects on immunity. Am J Clin Nutr

;73:444S‑50.

Walker WA. Mechanisms of action of probiotics. Clin Infect Dis

;46:S87‑91.

Karacaer F, Hamed I, Özogul F, Glew RH,

Özcengiz D. The function of probiotics on the treatment of

ventilator‑associated pneumonia (VAP): Facts and gaps. J Med

Microbiol2017;66:1275‑85.

Knight DJ, Gardiner D, Banks A, Snape SE, Weston VC,

Bengmark S, et al. Effect of synbiotic therapy on the incidence

of ventilator associated pneumonia in critically ill patients:

A randomised, doubleblind, placebo‑controlled trial. Intensive

Care Med 2009;35:854‑61.

Pitsouni E, Alexious V, Saridakis V, Peppas G, Falagas M. Does

the use of probiotics/synbiotics prevent postoperative infections

in patients undergoing abdominal surgery? A meta‑analysis of

randomized controlled trials. Eur J Pharmacol 2009;65:561‑70.

van Santvoort HC, Besselink MG, Timmerman HM, van

Minnen LP, Akkermans LM, Gooszen HG. Probiotics in surgery.

Surgery 2008;143:1‑7.

: Mahmoodpoor A, Hamishehkar H, Asghari R, Abri R,

Shadvar K, Sanaie S. Effect of a Probiotic Preparation on

Ventilator-Associated Pneumonia in Critically Ill Patients

Admitted to the Intensive Care Unit: A Prospective Double-Blind

Randomized Controlled Trial. Nutr Clin Pract 2019;34:156-62.

Liu KX, Zhu YG, Zhang J, Tao LL, Lee JW, Wang XD, et al. Probiotics’ effects on the incidence of nosocomial pneumonia in

critically ill patients: A systematic review and meta‑analysis. Crit

Care 2012;16:R109.

Golparvar M, Raoufi F. Evaluation of the effects of probiotics

on incidence of ventilator‑associated pneumonia in patients

hospitalized in intensive care unit. J Isfahan Med Sch

;37:593‑600.

Gu WJ, Wei CY, Yin RX. Lack of efficacy of probiotics

in preventing ventilator‑associated pneumonia. Chest

;142:859‑68.